Approximately 90 single nucleotide polymorphisms (SNPs) have been identified as associated with colorectal cancer risk. Individually they are not useful for discriminating those at high risk from those at low risk, however, in concert, they do have discriminatory power, especially for those at the tail ends of the distribution. Thus, polygenic risk scores have potential for targeting basing screening on individual risk – precision prevention. This presentation will discuss the progress in identifying additional SNPs, Estimates on the benefit of their use, and the challenges for implementation into health care.